# Icotrokinra clinical trial results for psoriasis > Live situation record from CLSTR: https://clstr.news/situations/icotrokinra-clinical-trial-results-for-psoriasis > Updated: 2026-10-09T13:53:34.000Z. Sources: 5. Developments: 2. Johnson & Johnson has released long-term Phase 3 clinical trial data for icotrokinra (Icotyde), an oral peptide designed to treat moderate-to-severe plaque psoriasis by blocking the interleukin (IL)-23 receptor. Data from the ICONIC-TOTAL trial, presented at the 2026 EADV Congress, highlighted sustained clearance in high-impact areas. At week 112, site-specific clearance rates reached 60% for the scalp, 89% for genitals, and 63% for hands and feet. Complementary results from the ICONIC-LEAD trial involving 684 participants showed that at least 72% maintained a PASI 90 response from week 64 through week 112. Additionally, 44% of patients achieved PASI 100, indicating complete skin clearance, while 78% reported sustained improvement in itch. The study also noted that 85% of patients who previously withdrew from the medication regained a PASI 90 response within 24 weeks of restarting treatment. Throughout both studies, no new safety signals were identified. ## Timeline ### 2026-10-09: Johnson & Johnson reports long-term efficacy for oral psoriasis drug Icotyde Johnson & Johnson’s Phase 3 ICONIC-LEAD trial shows icotrokinra (Icotyde) maintains at least 72% PASI 90 skin clearance through week 112 for moderate-to-severe plaque psoriasis patients. 4 sources. https://clstr.news/cluster/johnson-johnson-reports-long-term-efficacy-for-oral-psoriasis-drug-icotyde ### 2026-10-02: Icotrokinra shows sustained psoriasis clearance in 2-year trial Phase 3 trial data presented at EADV 2026 shows once-daily oral icotrokinra sustains psoriasis clearance in high-impact areas like the scalp and genitals through 112 weeks of treatment. 2 sources. https://clstr.news/cluster/icotrokinra-shows-sustained-psoriasis-clearance-in-2-year-trial --- Cite as: Icotrokinra clinical trial results for psoriasis. CLSTR, https://clstr.news/situations/icotrokinra-clinical-trial-results-for-psoriasis